血栓风险！FDA对强生新冠疫苗限制使用！

本月初，由于罕见但严重的血栓风险，FDA将强生新冠疫苗的使用限制在无法获得其他疫苗的18岁及以上人群。

Early this month, FDA limited the use of J&J’s COVID vaccine to those 18 and older who cannot access other vaccines, because of the threat of rare but serious blood clots.

Over a year ago, FDA paused its use because of the threat of thrombosis or thrombocytopenia syndrome (TTS), only 6 weeks after the product launch. The pause was lifted 10 days later with a warning attached to its use, because the benefit of the shot outweighed the risk.

关于博沃生物

博沃生物成立于2011年，致力于创新型人用疫苗的研发及产业化。公司管理和技术团队成员来自国内外知名生物制药企业或机构，平均20年以上行业经验，涉及研发、生产、质量管理、市场营销、采购物流、注册与知识产权等，经历过多次国内外机构的GMP认证检查，主持或参与过的生物医药项目近百个。

Founded in 2011, BravoBio is committed to the R & D and industrialization of innovative human vaccines. Members of the management and technical team come from well-known Biopharmaceutical Enterprises or institutions at home and abroad, with an average of more than 20 years of industry experience, involving R & D, production, quality management, marketing, purchasing, logistics, regulatory submissions and intellectual property rights, and rich experience of GMP inspections by domestic and foreign institutions. The Bravo team has led and/or participated in nearly 100 biopharmaceutical projects.